Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Expected to Rise, Guggenheim Analyst Says

Amylyx Pharmaceuticals (NASDAQ:AMLX) had its price objective increased by research analysts at Guggenheim from $40.00 to $55.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price objective points to a potential upside of 41.42% from the stock’s previous close.

A number of other analysts have also commented on the company. Mizuho lifted their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. HC Wainwright increased their target price on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday. Robert W. Baird raised their price objective on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Wolfe Research upgraded Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $36.25.

Amylyx Pharmaceuticals Price Performance

NASDAQ AMLX traded up $0.29 during mid-day trading on Wednesday, reaching $38.89. 3,483,750 shares of the stock were exchanged, compared to its average volume of 1,607,203. The stock has a 50 day simple moving average of $19.38 and a 200-day simple moving average of $16.35. Amylyx Pharmaceuticals has a one year low of $7.96 and a one year high of $39.93. The stock has a market cap of $4.33 billion, a P/E ratio of -27.20 and a beta of -0.21.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.03). Sell-side analysts anticipate that Amylyx Pharmaceuticals will post -1.45 EPS for the current fiscal year.

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of the stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the completion of the transaction, the insider owned 194,090 shares in the company, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Several large investors have recently made changes to their positions in AMLX. Meeder Asset Management Inc. purchased a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter worth approximately $25,000. KBC Group NV purchased a new stake in shares of Amylyx Pharmaceuticals in the first quarter worth $26,000. California State Teachers Retirement System bought a new position in shares of Amylyx Pharmaceuticals during the second quarter valued at $28,000. State of Wyoming purchased a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter worth about $40,000. Finally, Caitong International Asset Management Co. Ltd boosted its stake in Amylyx Pharmaceuticals by 954.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock worth $47,000 after purchasing an additional 3,493 shares in the last quarter. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Avexitide achieved the primary endpoint in the Phase 3 LUCIDITY trial for post-bariatric hypoglycemia, reducing hypoglycemic events by 55%. The result strengthens the case for an FDA filing by the end of 2026 and improves the drug’s potential commercial value. AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
• Positive Sentiment: Analysts raised their outlook for Amylyx. HC Wainwright maintained a Buy rating and a $55 price target while increasing its EPS forecasts to $3.22 for 2029 and $6.40 for 2030, reflecting expectations for successful commercialization and substantially higher future revenue. HC Wainwright Raises Amylyx Price Target
• Positive Sentiment: Guggenheim raised its price target to $55 from $40 with a Buy rating, while Robert W. Baird increased its target to $52 from $28 and assigned an Outperform rating. Wolfe Research also upgraded the shares to Strong Buy, adding to the positive analyst momentum.
• Neutral Sentiment: The clinical success has pushed AMLX toward regulatory and commercial execution milestones. Investors will now focus on additional LUCIDITY data, the FDA filing, approval prospects and Amylyx’s ability to establish avexitide commercially.
• Negative Sentiment: Amylyx priced an upsized public offering of 14.09 million shares at $35.50 per share, expected to raise approximately $500 million before expenses. Underwriters may purchase another 2.11 million shares, creating potential dilution and adding supply near the offering price. Amylyx Prices Upsized $500 Million Offering

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research has centered on therapies intended to protect nerve cells and address the underlying biology of conditions such as amyotrophic lateral sclerosis (ALS) and other serious neurological disorders.

Amylyx’s lead product, AMX0035, was marketed in the United States as Relyvrio and in Canada as Albrioza for the treatment of ALS. Following results from a confirmatory clinical trial that did not meet its objectives, the company announced the voluntary withdrawal of the product from the market in 2024.